MONMOUTH JUNCTION, N.J. - Oct. 31, 2020 - Biotech Support Group reports on a patent application relevant to how membrane proteases coordinate cell entry of the SARS-CoV-2 (Covid-19) virus. The patent disclosure describes new methods of proteomic analysis that can monitor how the body's protease inhibitors are pre-disposed (or not), to suppress this entry mechanism, with potential for biomarkers to clinically manage severe disease and guide therapeutic development.
The US provisional patent application is entitled "Methods to Monitor Functional Subforms of Serine Protease Inhibitors from Biofluids during Viral Infections", filed on October 27, 2020.
Serine proteases are enzymes that irreversibly cleave proteins, and thus play critical roles in many key biological processes including digestion, blood coagulation, and immunity. During stress or inflammation, many proteases are secreted into the general circulation, while others are cell membrane bound; the largest group being the Type II Transmembrane Serine Proteases (TTSPs). TTSPs play a critical cooperative role in viral infectivity of influenza and coronaviruses and most especially in the SARS-CoV-2 (Covid-19) pandemic.
The purpose and scope of this patent application is to:
>develop clinically actionable blood (and other accessible biofluids) biomarkers for viral infections that have a cell entry mechanism which utilize Type II Transmembrane Serine Proteases (TTSPs) as priming components, through proteomic measurement of functional subforms of the major inhibitory proteins that regulate protease storms - the Serpins, and
>utilize one or more proteomic patterns from these Serpin subforms as biomarkers for precision medicine to clinically manage viral infections.
"This new provisional patent amplifies the proteomic methods we have developed to measure Serpin function by differentiating active vs. inactive Serpins from blood and other biofluids. While soluble serine proteases are released from systemic granulocytic cargo during the innate immune response, some viruses and especially SARS-CoV-2, utilize membrane bound serine proteases to gain entry into host cells and cause clinical pathology. In this context, a better understanding of the physiological relevance of endogenous inhibitors, like Alpha-1-Antitrypsin (SerpinA1) and other Serpins in Covid-19, will be exceedingly important as biomarkers to monitor the potential for severe disease, and in the development of new anti-Covid-19 therapeutic strategies. For this purpose, our new patent application will present a more complete picture of the functional profile of Serpin activity, and we welcome inquiries for its use.", states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. For more information, go to http://www.biotechsupportgroup.com.
For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com
Contact
Biotech Support Group LLC
